

Amendments to the Specification:

Please insert the following new section immediately before the section entitled “Technical Field” at page 1, line 8:

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 440077_401USPC_SEQUENCE_LISTING.txt. The text file is 39 KB, was created on June 4, 2009, and is being submitted electronically via EFS-Web.

Please replace the paragraph beginning at page 78, line 28 with the following paragraph:

Vectors and transfection of cells. The mouse CD83 (mCD83) gene was amplified from anti-CD3 monoclonal antibody-activated mouse spleen cells using primer GTGTCGCAGCGCTCCAGCC [SEQ ID NO:17—] and primer GGCATTCAGGCACACTGATC [SEQ ID NO:18—] (Twist et al., *Immunogenetics* 48:383-93 (1998)). An amplified cDNA fragment was first cloned into pGEM-T easy vector (Promega, Madison, WI) and verified by DNA sequencing, after which the mouse CD83 gene was cloned into pLNCX2 vector (BD Biosciences Clontech, Palo Alto, CA) and pLenti6/V5 vector (Invitrogen™ Life Technologies, Carlsbad, CA). Transfection of a packaging cell line and infection of target cell lines (including cells from the M2 clone of K1735 cells) were performed according to the manufacturer’s recommendations.

Please replace the paragraph beginning at page 79, line with the following paragraph:

To produce mCD83 Ig fusion protein, the mouse CD83 extracellular domain (ECD) [SEQ ID NO:21—] (positions 1-134 of SEQ ID NO: 6) was amplified from the mouse CD83 gene using primer AAGCTTCCAGCCATGTCGCAAGGCCTC [SEQ ID NO:19—] and

GGATCCGCCCTGTACTTCCTG [SEQ ID NO:20—]. The amplified fragment was first cloned into pCR-topo vector (Invitrogen Life Technologies), and the nucleotide sequence was verified by standard DNA sequencing technique. Mouse CD83 ECD was cloned into pD18-mIgG (IgG_{2a} isotype) vector and was transfected into COS-7 cells to produce mCD83-ECD-mIgG fusion protein, which was subsequently purified using Protein A Sepharose 4B (Sigma Aldrich, St. Louis, MO).